Close Menu
Healthtost
  • News
  • Mental Health
  • Men’s Health
  • Women’s Health
  • Skin Care
  • Sexual Health
  • Pregnancy
  • Nutrition
  • Fitness
What's Hot

AI converts sights for visual impairments

June 9, 2025

30 minutes Kettlebell Core Workouts to strengthen your abdomen

June 9, 2025

Semaglutide for Weight Loss – Summer Safety and Side Effects Guide

June 9, 2025
Facebook X (Twitter) Instagram
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Disclaimer
Facebook X (Twitter) Instagram
Healthtost
SUBSCRIBE
  • News

    AI converts sights for visual impairments

    June 9, 2025

    AI model detects brain tumors with high precision using epigenetic fingerprints

    June 8, 2025

    The new study warns long -term risks from germ transplants

    June 8, 2025

    Self-collection tests could be a solution to increase access to cervical cancer control

    June 7, 2025

    Preeclampsia associated with long -term brave disbelief and worsening the effects of stroke

    June 7, 2025
  • Mental Health

    Heart attack or panic attack? Why do young people call ambulances for non -managed stress

    June 7, 2025

    My journey, my development, my truth – uninterrupted

    June 6, 2025

    Why I am fighting for mental health change

    June 3, 2025

    Girls with painful periods are twice as high as their peers to have symptoms of anxiety or depression

    June 2, 2025

    Does psychiatric drug kill creativity? Rejecting Van Gogh’s myth

    May 29, 2025
  • Men’s Health

    30 minutes Kettlebell Core Workouts to strengthen your abdomen

    June 9, 2025

    Scientists identify genetic indications that connect air pollution to neurodegeneration

    June 7, 2025

    Do you want a stronger back? This Powerlifter’s secret weapon is a secret weapon

    June 7, 2025

    Chains, bands and greater profits: Guide to deal with resistance

    June 6, 2025

    Phil Stutz, True Magic & Healing Mankind: Useful tools for today’s World – Part 2: Universe 1 and Universe 2

    June 6, 2025
  • Women’s Health

    Making the connection between collagen and recovery from exercise

    June 8, 2025

    Alice Connors for purpose and progress

    June 4, 2025

    8 teenagers of vitamins must actually get

    June 4, 2025

    Reasons for frequent urination

    June 3, 2025

    Life with myalgian encephalomyelitis/chronic fatigue syndrome

    June 3, 2025
  • Skin Care

    Semaglutide for Weight Loss – Summer Safety and Side Effects Guide

    June 9, 2025

    10 signs it’s time to see an acne expert

    June 8, 2025

    11 Important facts for Botox Botox hood

    June 7, 2025

    Liposcopy: Is it right for you?

    June 7, 2025

    Ideas for father’s day and beyond

    June 4, 2025
  • Sexual Health

    Teenagers and sexual education during the Covid-19 pandemic and beyond

    June 9, 2025

    The odd rise of cases of syphilis to heterosexual men in the UK

    June 8, 2025

    The Role of Certified LGBTQ Certified Sexual Therapist – Sexual Health Alliance

    June 7, 2025

    How Pride paved the way for sexual well -being

    June 5, 2025

    Best male masturbation positions Female

    June 4, 2025
  • Pregnancy

    Love in Melbourne Australia – Tiffany Rose Maternity Blog UK

    June 8, 2025

    How to remain calm with high blood pressure during pregnancy?

    June 7, 2025

    Pink Stork’s flagship product – as shown in “Empowered by Meg Ryan”

    June 7, 2025

    You don’t have to know everything – only that before birth

    June 6, 2025

    Top 100 Names of Girls 2024

    June 5, 2025
  • Nutrition

    The busy mom’s driver for intestinal-brain connection

    June 7, 2025

    Healthy Banana Bread (Child Approved) Sarah Remat

    June 6, 2025

    The secret to the loss of persistent belly fat by registered dieticians

    June 5, 2025

    Why are you always tired and what to do

    June 5, 2025

    20 herbal and wonderful recipes with appetizers

    June 4, 2025
  • Fitness

    Creamy all the toast Avocado bagel (easy, salty breakfast!)

    June 8, 2025

    Men’s Health Month: Dealing longevity vacuum

    June 7, 2025

    Best 12 biceps exercises ranked: build larger and stronger weapons

    June 6, 2025

    Próximamente el 10 de junio: 25 minutes of train de Joel Freeman

    June 5, 2025

    The best weight counter to add to your home gym in your 2025

    June 5, 2025
Healthtost
Home»News»GLP-1 and SGLT2 inhibitors show promise in preventing recurrent strokes and heart attacks
News

GLP-1 and SGLT2 inhibitors show promise in preventing recurrent strokes and heart attacks

healthtostBy healthtostNovember 11, 2024No Comments8 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
Glp 1 And Sglt2 Inhibitors Show Promise In Preventing Recurrent Strokes
Share
Facebook Twitter LinkedIn Pinterest WhatsApp Email

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of drugs most commonly prescribed to treat type 2 diabetes or weight loss, may reduce the risk of heart attack, second stroke and death in adults who have had an initial stroke episode, according to a preliminary study. to be presented at the 2024 American Heart Association Scientific Sessions. The meeting, November 16-18, 2024, in Chicago, is a leading global exchange of the latest scientific advances, research and evidence-based clinical practice updates in cardiovascular science.

Unfortunately, a quarter of people who survive a stroke will have another stroke and are also at risk for other cardiovascular events, such as a heart attack, as many of the risk factors for a stroke are also associated with other forms of heart disease. Managing these risks, as well as considering innovative approaches to reduce the chances of another stroke, heart attack, or death in this population are all critical steps in increasing stroke survival and improving the quality of life for people who have suffered a stroke”.


M. Ali Sheffeh, MD, lead study author, an internal medicine physician and researcher at the Mayo Clinic in Rochester, Minnesota

In this study, Sheffeh and colleagues evaluated whether two classes of drugs to treat Type 2 diabetes are associated with a reduced risk of heart attack, second stroke, or death in stroke survivors.

One class of drugs – glucagon-like peptide-1 (GLP-1) receptor agonists – treats type 2 diabetes by stimulating the release of insulin from the pancreas, delaying stomach emptying and reducing the release of glucagon, a hormone in the body that increases the blood sugar.

The GLP-1 drugs liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic polypeptide (GIP) tirzepatide, have been approved by the US Food and Drug Administration for weight loss and cardiovascular disease risk reduction in humans with obesity or overweight.

The other class of drugs, sodium-glucose cotransporter 2 (SGLT2) inhibitors, lowers blood sugar levels by prompting the kidneys to remove excess glucose from the body through the urine. The SGLT2 drugs canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin are FDA-approved for the treatment of type 2 diabetes.

To analyze the impact of these two classes of drugs, this study reviewed the medical records of more than 7,000 adults who had strokes caused by blood clots or ischemic strokes between January 2000 and June 2022. All participants had received stroke care at hospitals in multiple systems. of health in Minnesota or Wisconsin. The researchers evaluated the results for people who were prescribed either a GLP-1 drug or an SGLT2 drug after their initial stroke to determine if there was a potential impact on their risk of having a second stroke, heart attack, or death.

After an average follow-up of three years, the analysis found:

  • Adults taking either GLP-1 or SGLT2 had a 74% lower risk of death and an 84% lower risk of heart attack.
  • Adults taking SGLT2 also had a 67% lower risk of having another stroke.
  • All of the reduced risks noted were present even when the researchers accounted for other factors that may have influenced or increased some patients’ risk. These included age, gender, smoking status, hypertension status, type 2 diabetes status, peripheral arterial disease, hyperlipidemia, chronic kidney disease, and history of heart attack or history of heart failure.
  • Over the entire study period, the death rate among stroke survivors who received either GLP-1 or SGLT2 was 11.8%, compared with 54% among patients who received neither class of drugs. The rate of heart attacks among patients who received any drug was also 1.5%, compared with 6.1% among patients who did not receive any class of drug.
  • The rate of another stroke was similar between patients who received and received no drug, at about 6%.

“When we compared multiple variables, we could still conclude that treatment with any drug was associated with a lower risk of recurrent stroke, even though the rate was similar between patients who received and did not receive any drug,” Sheffeh said. He noted that the drugs significantly reduced the risk of recurrent stroke in an analysis that compared multiple variables, including patients’ risk factors for recurrent stroke—age, gender, hypertension status, type 2 diabetes status, peripheral artery disease, and a history of heart attack or heart failure . However, the risk of recurrent stroke was not significantly lower in an analysis comparing drug use with recurrent stroke and no additional variables.

“Potential protective effects of the drugs were hidden because those in the treatment group may have more high-risk characteristics than patients taking no drug, obscuring any protective effect. What multivariate adjustment does is take these differences into account and to tease out any independent effect,” Shefeh said. “The study results are consistent with other research on the preventive role of these drugs against cardiovascular disease in people with obesity or heart failure’.

The researchers also conducted a subanalysis of patients who took the drugs for at least six months to confirm whether the drugs’ association with a lower risk of heart attack, recurrent stroke, and death could be attributed to the drugs. The results were similar to those of the original study: the drugs were associated with a lower risk of heart attack, recurrent stroke and death, Sheffeh noted.

Background and study details:

  • The study included health data on 7,044 adults hospitalized for acute ischemic stroke between January 2000 and June 2022 in the Rochester Epidemiology Project. The database collects data from a partnership of clinics, hospitals and other medical facilities, including those of the Mayo Clinic, Olmstead Medical Center, Olmsted County Public Health Services or Zumbro Valley Health Center in Minnesota, as well as the Mayo Clinic Sealth System in Wisconsin.
  • The participants were on average 72 years old. 52% identify as male and 48% identify as female. 94% identify as white adults, 1.5% as black adults, 1.5% as Asian adults, and 3% as “other” race adults.

Limitations of the study include that the analysis was conducted on health data for people treated in one US health system and that most patients in the analysis were white and from one geographic region, meaning the results may not apply to people living in other places or people of other races or ethnicities. In addition, the database did not show why patients were prescribed either drug, although 93 percent of patients who received either drug had type 2 diabetes, Sheffeh noted. The researchers were also unable to assess the burden that stroke had on each patient because this information was not available in the database.

Stroke is the leading cause of disability and the fifth leading cause of death in the US Ischemic strokes, which account for about 85% of all strokes, are caused by a lack of blood flow to the brain due to a clot. This occurs when a vessel that supplies blood to the brain becomes blocked by plaque or fatty deposits within the vessel wall. Plaque can either cause blood vessels to narrow, which blocks blood flow, or cause a clot to break off in another part of the body and travel to smaller vessels near the brain, where it causes a blockage.

“For several years, we have seen from randomized controlled trials that SGLT2 inhibitors and GLP-1 receptor agonists have the ability to reduce the risk of cardiovascular disease, including stroke, heart attack, and death. These new findings are consistent with what we would expect and we have seen that these effects are evident in patients with type 2 diabetes and obesity and in obese patients without type 2 diabetes,” he said. Cheryl Bushnell, MD, MHS, FAHA, professor and vice chair for research in the department of neurology at Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Bushnell is chair of the writing group for the Society’s 2024 Guideline for Primary Stroke Prevention, which details a variety of prevention strategies for people without a prior history of stroke. The new guideline provides evidence-based recommendations for strategies to support brain health and prevent stroke throughout a person’s lifetime by improving healthy lifestyle behaviors and preventive care.

Bushnell also noted the ability of GLP-1 receptor agonists to lower blood pressure and reduce plaque formation associated with atherosclerosis, a risk factor for heart attack and stroke. “Another mechanism that could be very important to this current study is that GLP-1 receptor agonists can actually reduce platelet aggregation, and that in itself could reduce the risk of thrombosis and lead to lower stroke risk,” he said. he said. “We need a clinical trial to know if these SGLT2 inhibitors and GLP-1 receptor agonists could actually change practice, how we can help patients prevent a second or recurrent stroke. These drugs may be very important, however, we don’t have that data yet.”

Source:

American Heart Association

attacks GLP1 heart inhibitors Preventing promise recurrent SGLT2 show strokes
bhanuprakash.cg
healthtost
  • Website

Related Posts

AI converts sights for visual impairments

June 9, 2025

AI model detects brain tumors with high precision using epigenetic fingerprints

June 8, 2025

The new study warns long -term risks from germ transplants

June 8, 2025

Leave A Reply Cancel Reply

Don't Miss
News

AI converts sights for visual impairments

By healthtostJune 9, 20250

Breakthrough AI transforms the way people with visual damage experience the world, giving them tools…

30 minutes Kettlebell Core Workouts to strengthen your abdomen

June 9, 2025

Semaglutide for Weight Loss – Summer Safety and Side Effects Guide

June 9, 2025

Teenagers and sexual education during the Covid-19 pandemic and beyond

June 9, 2025
Stay In Touch
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
TAGS
Baby benefits body brain cancer care Day Diet disease exercise finds Fitness food Guide health healthy heart Life Loss Men mental Natural Nutrition Patients Pregnancy protein research reveals Review risk routine sex sexual Skin study Therapy Tips Top Training Treatment Understanding ways weight women Workout
About Us
About Us

Welcome to HealthTost, your trusted source for breaking health news, expert insights, and wellness inspiration. At HealthTost, we are committed to delivering accurate, timely, and empowering information to help you make informed decisions about your health and well-being.

Latest Articles

AI converts sights for visual impairments

June 9, 2025

30 minutes Kettlebell Core Workouts to strengthen your abdomen

June 9, 2025

Semaglutide for Weight Loss – Summer Safety and Side Effects Guide

June 9, 2025
New Comments
    Facebook X (Twitter) Instagram Pinterest
    • About Us
    • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Disclaimer
    © 2025 HealthTost. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.